ACAD Projected Dividend Yield
Acadia Pharmaceuticals Inc ( NASDAQ : ACAD )Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system disorders. Co. has a portfolio of product including its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. NUPLAZID is a selective serotonin inverse agonist/antagonist, targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. 20 YEAR PERFORMANCE RESULTS |
ACAD Dividend History Detail ACAD Dividend News ACAD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |